AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer
Resolved · regulation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-29. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
Regulatory submission initiates the FDA review clock, creating prospective milestone payments and royalty expansion for HUTCHMED and expanding AstraZeneca's oncology revenue base.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factAstraZeneca submitted a New Drug Application (NDA) to the US FDA for ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib). |
| What else was confirmed? | Reported factThe submission targets MET-driven, EGFR-mutated non-small cell lung cancer in patients who progressed following EGFR-TKI therapy. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for HCM yet — this is the next research task. |
| What would change the assessment? | UnknownFDA NDA acceptance and PDUFA date assignment — Official FDA notification of NDA filing acceptance and assignment of standard vs priority review status |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · AstraZeneca submitted a New Drug Application (NDA) to the US FDA for ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib).
- · The submission targets MET-driven, EGFR-mutated non-small cell lung cancer in patients who progressed following EGFR-TKI therapy.
- · The NDA filing is partnered with HUTCHMED, which co-developed savolitinib.
Public research record
Research framework · page evidenceCompleted event assessment
milestone cash flows and US commercial royalty visibility on FDA regulatory advancement
| Type | Claim | Scope |
|---|---|---|
| Assumption | AstraZeneca submitted a New Drug Application (NDA) to the US FDA for ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib). | 2026-09-29 |
| Interpretation | milestone cash flows and US commercial royalty visibility on FDA regulatory advancement | HCM |
Countercase, invalidators, and sources
FDA grants Priority Review designation, accelerating US commercialization timeline to early 2027.
- · FDA NDA acceptance and PDUFA date assignment — Official FDA notification of NDA filing acceptance and assignment of standard vs priority review status
- HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO · 2026-09-29
What remains unresolved
- Base path
- Standard 10-month PDUFA review timeline proceeds with advisory committee review scheduling.
- Adverse path
- FDA issues complete response letter requesting additional efficacy or biomarker stratification data.
- Supportive path
- FDA grants Priority Review designation, accelerating US commercialization timeline to early 2027.
- · FDA NDA acceptance and PDUFA date assignment — Official FDA notification of NDA filing acceptance and assignment of standard vs priority review statusthis week
Evidence
- HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO2026-09-29
“HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer.”
Supports: AstraZeneca submitted US NDA to FDA for savolitinib plus osimertinib combo in MET-driven EGFR lung cancer